Operational Highlights Revenues from operations stood at ₹394 Cr in Q3FY21 with gross margins at 26.64% and EBITDA margins at 15.32% The rise in input cost was overcome as a result of cost improvement. Addition of ₹2.2Cr one time exceptional expense for Mahad overflooded facility Insurance claims are expected and will be reflected in March …
Operational Highlights Revenues stood at ₹1356 Cr, 17% growth YoY from ₹1162 Cr in Q3FY21 EBITDA grew by 8% YoY to ₹297 Cr 19% growth in export business and 8% growth in domestic business Overhead increased by 24% mainly attributed to increase in power and other utility cost Hike in selling prices partially cover the …
Operational Highlights The quarter was challenging due to high input costs Revenue from operation stood at ₹205.8 Cr degrowth of (10.7%) QoQ and 7.9% growth YoY EBITDA margins at 7.87% compared to 8.59% in previous quarter Strong demand witnessed across all product categories, resulting in a better top line growth compared to the same period …
Operational Highlights Highest quarterly revenue of ₹132.6 Cr, growth of 56% YoY EBITDA grew by 41% YoY to ₹23.8 Cr robust revenue gains driven by higher contribution from recently commissioned phase I & II expansions at Dahej SEZ EBITDA performance includes transient cost impact related to Phase I & II expansion. This will be neutralised …
Operational Highlights Operating revenues stood at ₹367 Cr registering growth of 24% YoY EBITDA grew by 21% YoY to ₹98 Cr with margins at 27% 58% of revenue contribution from high value business and rest 42% from legacy business Growth momentum of 10% YoY in high value business and 50% in legacy businesses As per …
Operational Highlights Despite the challenging business environment, Meghmani Organics Ltd. (MOL) revenue grew by 43.7% YoY to ₹ 640 Cr in Q3 FY22 aided by higher realisation from Pigments along with improvement in volume & higher realisation from Agrochemicals business. As an industry wide phenomenon, MOL too faced the challenge in respect to hardening of …
Net revenues for the quarter were ₹348.6 Cr (4.6% growth YoY). EBITDA for the quarter stood at ₹73.4 Cr and EBITDA margin for the quarter was 21.1%.PAT for the quarter was ₹33 Cr and PAT margins were 9.5%. Revenues from domestic formulation business for the quarter was ₹181.5 Cr (15.2% growth YoY). Major therapeutic segments …
Operational Highlights Revenue from operations stood at ₹860 Cr attributing to growth of 95% YoY EBITDA stood at ₹118.7 Cr with EBITDA margins at 14% Bounce back from the setback caused due to floods in previous quarter Both the business performed strongly Import duty on prime raw material “acetic acid” is now reduced from 7.5% …
Operational Highlights The revenues for Q3FY22 stood at ₹429.4Cr from ₹310.3 Cr in same period previous year accounting to growth of 38.4% YoY EBITDA for the quarter stood at ₹48.5Cr translating to EBITDA margins of 11.29% . The contributors to Consolidated Net Profit after tax of ₹106.02Crore in Q3-FY22 include share of profit of DyStar …
Net revenues for the quarter were ₹348.6 Cr (4.6% growth YoY). EBITDA for the quarter stood at ₹73.4 Cr and EBITDA margin for the quarter was 21.1%.PAT for the quarter was ₹33 Cr and PAT margins were 9.5%. Revenues from domestic formulation business for the quarter was ₹181.5 Cr (15.2% growth YoY). Major therapeutic segments …